Development and Characterization of a Novel Congenital Acute Erythroid Leukemia Cell Line with Unique Features

Area of Science:

• Hematology
• Oncology
• Cell Biology

Background:

• Acute Erythroid Leukemia (AEL), or AML-M6, is a rare subtype predominantly affecting adults and is understudied in pediatric populations.
• A novel AEL cell line, LS-CHM, was successfully established from the ascitic fluid of a patient with congenital leukemia.
• Leukemic cells in LS-CHM demonstrated persistence in ascites, even after clearance from bone marrow and extramedullary sites.

Purpose of the Study:

• To establish and characterize a novel cell line model for congenital Acute Erythroid Leukemia (AEL).
• To provide a unique model for studying pediatric and extramedullary AEL.
• To facilitate further biologic and therapeutic investigations into AEL.

Main Methods:

• Characterization of LS-CHM cells using flow cytometry, cytogenetics, cell cycle analysis, and sequencing (genome, RNA, myeloid genes).
• Assessment of proliferation, cytokine independence, colony formation, and chemosensitivity.
• Development of a patient-derived xenograft (PDX) mouse model.

Main Results:

• LS-CHM cells exhibited robust in vitro growth, specific immunophenotype (CD36, partial CD235a, CD31, CD43, CD71), and sensitivity to chemotherapy.
• Genomic analysis revealed a frameshift BCOR mutation and downregulated TP53 expression.
• RNA sequencing identified upregulation of cohesin complex genes (RAD21, SMC3), linked to erythroid differentiation.

Conclusions:

• LS-CHM is the first congenital AEL cell line, distinct from predominantly adult-origin lines.
• This cell line serves as a valuable pediatric and extramedullary AEL model.
• LS-CHM presents significant opportunities for advancing AEL research and treatment strategies.